Abstract: A non-toxic, topical antifungal composition and use of the composition for treating infections comprising a combination of at least three or more low molecular weight, hydrophilic organic acid salts and/or derivatives exhibiting a synergistic enhancement, dissolved in a carrier, wherein the low molecular weight organic acid salts are selected from the group consisting of saturated and unsaturated, acyclic, branched and unbranched aliphatic carboxylic acids wherein the longest carbon chain has eight carbons, and aromatic carboxylic acids containing less than ten carbon atoms; the carrier comprises one or more non-aqueous, non-volatile polyhydric solvents; and wherein the combination of low molecular weight, hydrophilic organic acid salts or derivatives comprises between about 0.5% to about 50 by weight of the composition, and no single acid salt or derivative comprises more than about 75% by weight of the total acid content.

Abstract: The present invention provides oligomers of phosphorylated insulin and formulations thereof. The oligomeric derivatives of the invention exhibit pharmacodynamic properties that are significantly improved over native insulin or other intermediate-acting or basal insulins, for example NPH, Lantus or Detemir, in that they demonstrate a 4-fold higher therapeutic index and a 4-fold lower risk of hypoglycemia. The invention provides the advantage of protracted glycemic lowering and combines it with the advantage of reduced hypoglycaemic risk. The above is not a property of any presently-known or available basal or intermediate-acting insulin. In a further embodiment of the invention, formulations of oligomeric phosphorylated insulin are suitable for all routes of administration including inhalation, buccal absorption, subcutaneous injection, infusion or other technically proven routes for insulin administration.

Abstract: A process for phosphorylating a peptide comprises reacting an aqueous solution of the peptide with an effective amount of phosphorous oxychloride under conditions favoring phosphorylation of the peptide. In a specific embodiment, the peptide is insulin. A phosphorylated insulin is used in the treatment of diabetes mellitus wherein the phosphorylated insulin is produced or purified with an effective amount of phosphorus oxychloride to have substantially reduced iso-electric points and to have the property of reducing hyperglycemia without substantially inducing hypoglycemia. In a specific embodiment of the invention, the method comprises administering to a human being an effective therapeutic amount of a phosphorylated insulin essentially free of unmodified insulin and having substantially reduced iso-electric points whereby hyperglycemia is reduced substantially without inducing hypoglycemia.

Abstract: A method of non-invasive determination of the concentration of at least one analyte in the blood of a mammal, includes the steps of projecting near-infrared radiation on a portion of the body of the mammal, the radiation including a plurality of wavelengths; sensing the resulting radiation emitted from the portion of the body; deriving from the sensed resulting radiation emitted from the portion of the body a first expression for the magnitude of the sensed radiation as a function of wavelength of the sensed radiation; pretreating the first expression to minimize the influence of offset and drift to obtain a second expression for the magnitude of the sensed radiation as a function of wavelength; and performing multivariate analysis of the second expression to obtain a value for the concentration of the analyte.

Abstract: The present invention is directed to a solution of a polypeptide, such as, for example, insulin, the solution being prepared and maintained at pH 6.8 to 8.0 and in which the polypeptide remains in solution in disaggregated form. This is accomplished by the use of the bicarbonate ion in the solution, the bicarbonate ion being present in a concentration of 2 mmolar to 2.5 molar.A method for preparing the polypeptide solution and the use of the solution in maintaining normoglycemia are provided.